Invesco Ltd. Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Invesco Ltd. purchased a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,065 shares of the company’s stock, valued at approximately $133,000.

Several other hedge funds have also recently made changes to their positions in STOK. Bank of New York Mellon Corp raised its stake in Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after acquiring an additional 1,330 shares during the period. Rhumbline Advisers lifted its stake in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after purchasing an additional 2,787 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Stoke Therapeutics by 29.2% during the fourth quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company’s stock valued at $220,000 after buying an additional 4,512 shares during the last quarter. Wells Fargo & Company MN raised its stake in Stoke Therapeutics by 51.2% during the fourth quarter. Wells Fargo & Company MN now owns 16,786 shares of the company’s stock valued at $185,000 after purchasing an additional 5,682 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics in the fourth quarter worth about $63,000.

Stoke Therapeutics Stock Up 0.7 %

Shares of NASDAQ STOK opened at $9.70 on Tuesday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $17.58. The business’s 50 day moving average price is $7.93 and its 200 day moving average price is $10.14. The firm has a market cap of $529.59 million, a P/E ratio of -4.62 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on STOK shares. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Chardan Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $24.67.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.